Heart flutters may weaken lungs and muscles, new study suggests
NCT ID NCT07396597
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study looks at how premature ventricular complexes (extra heartbeats) impact breathing, muscle strength, physical activity, and quality of life. Researchers will measure lung function, cough strength, handgrip strength, and daily activity in 52 adults with this condition. The goal is to better understand the full-body effects of PVCs, not to test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 52 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population consists of adults including individuals diagnosed with symptomatic premature ventricular complexes and healthy control participants. Participants will be recruited from patients presenting to the Cardiology Department of Buca Seyfi Demirsoy Training and Research Hospital and volunteers without premature ventricular complexes.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for Individuals with Premature Ventricular Complexes (PVCs): * Aged between 18 and 80 years * Presence of symptomatic premature ventricular complexes resistant to ≥1 antiarrhythmic medication (including β-blockers and calcium channel blockers) * Premature ventricular complex burden ≥10% * Ventricular arrhythmias originating from any focus within the right or left ventricle * Physically able to participate in all study assessments * Willingness to participate in the study by providing written informed consent Inclusion Criteria for Control Group Participants: * Aged between 18 and 80 years * Healthy individuals * Willingness to participate in the study * Physically able to participate in all study assessments Exclusion Criteria for Individuals with Premature Ventricular Complexes (PVCs): * Left ventricular ejection fraction (LVEF) \<45% unless PVC-induced cardiomyopathy is documented (defined as a \>15% improvement in LVEF following reduction of PVC burden through pharmacological therapy or ablation) * Progressive decline in LVEF within the last 4 months, regardless of etiology * Severe heart failure classified as New York Heart Association (NYHA) Class ≥III * Ventricular arrhythmias attributed to underlying structural heart disease, known myocardial scar, or myocarditis * Change in the dosage of antiarrhythmic medications (including β-blockers and calcium channel blockers) within 2 months prior to enrollment * Failed catheter ablation within 3 months prior to enrollment * Known thyroid disorders or individuals undergoing renal dialysis * Life expectancy \<12 months * Presence of angina pectoris * Diagnosis of chronic obstructive pulmonary disease (COPD) or asthma * Resting heart rate \>120 beats/min * Resting systolic blood pressure ≥180 mmHg * Resting diastolic blood pressure ≥100 mmHg * Resting peripheral oxygen saturation ≤90% Exclusion Criteria for Control Group Participants: * Presence of premature ventricular complexes * Presence of any acute or chronic medical condition
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Premature ventricular complexes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Izmir Democracy University
Izmir, 35140, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.